Wellington Management Group LLP Buys 1,125,454 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Wellington Management Group LLP increased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 4.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,345,680 shares of the company's stock after purchasing an additional 1,125,454 shares during the quarter. Wellington Management Group LLP owned approximately 9.53% of Autolus Therapeutics worth $59,562,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of AUTL. Jane Street Group LLC purchased a new position in Autolus Therapeutics in the 4th quarter worth about $26,000. Barclays PLC increased its stake in Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after purchasing an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC purchased a new position in Autolus Therapeutics in the 4th quarter worth about $35,000. Daiwa Securities Group Inc. increased its stake in Autolus Therapeutics by 55.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its stake in Autolus Therapeutics by 29.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after purchasing an additional 6,081 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AUTL. Truist Financial lowered their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Wells Fargo & Company lowered their target price on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday, March 21st. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL traded down $0.01 during trading hours on Friday, hitting $1.74. The stock had a trading volume of 1,685,155 shares, compared to its average volume of 1,507,688. The company has a market capitalization of $463.09 million, a P/E ratio of -1.44 and a beta of 1.77. The firm's 50-day moving average price is $1.41 and its two-hundred day moving average price is $2.00. Autolus Therapeutics plc has a 52 week low of $1.11 and a 52 week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. As a group, analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.